BRPI0915813A2 - estabilizante e composição de vacina compreendendo um ou mais flavivírus atenuados vivos - Google Patents

estabilizante e composição de vacina compreendendo um ou mais flavivírus atenuados vivos

Info

Publication number
BRPI0915813A2
BRPI0915813A2 BRPI0915813-8A BRPI0915813A BRPI0915813A2 BR PI0915813 A2 BRPI0915813 A2 BR PI0915813A2 BR PI0915813 A BRPI0915813 A BR PI0915813A BR PI0915813 A2 BRPI0915813 A2 BR PI0915813A2
Authority
BR
Brazil
Prior art keywords
vaccine composition
stabilizer
live attenuated
vaccine
attenuated flaviviruses
Prior art date
Application number
BRPI0915813-8A
Other languages
English (en)
Inventor
Francon Alain
Brass Olivier
Chouvenc Pierre
Leleu Amandine
Original Assignee
Sanofi Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Pasteur filed Critical Sanofi Pasteur
Publication of BRPI0915813A2 publication Critical patent/BRPI0915813A2/pt
Publication of BRPI0915813B1 publication Critical patent/BRPI0915813B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24151—Methods of production or purification of viral material
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

estabilizante para composições de vacina, composição de vacina aquosa em massa estabilizada, método de estabilização de um ou mais flavivírus atenuados vivos, composição de vacina seca, método para a preparação de uma vacina e kit de vacina flaviviral a presente invenção refere-se a um estabilizante para composições de vacina compreendendo um ou mais flavivírus atenuados vivos, a uma composição de vacina em massa estabilizada com este estabilizante, particularmente uma composição de vacina seca preparada a partir desta composição da vacina em massa, e a um método para a estabilização de um ou mais flavivírus atenuados vivos.
BRPI0915813-8A 2008-07-09 2009-07-09 Estabilizante para composições de vacina, composição de vacina aquosa em massa estabilizada, método de estabilização de um ou mais flavivírus atenuados vivos, composição de vacina seca, métodos para a preparação de vacinas e kit de vacina flaviviral BRPI0915813B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08305390.0 2008-07-09
EP08305390A EP2143440A1 (fr) 2008-07-09 2008-07-09 Agent stabilisant et composition vaccinale comprenant un ou plusieurs flavivirus vivants atténués
PCT/EP2009/004980 WO2010003670A1 (en) 2008-07-09 2009-07-09 Stabilizer and vaccine composition comprising one or more live attenuated flaviviruses

Publications (2)

Publication Number Publication Date
BRPI0915813A2 true BRPI0915813A2 (pt) 2019-04-09
BRPI0915813B1 BRPI0915813B1 (pt) 2022-02-08

Family

ID=39942863

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0915813-8A BRPI0915813B1 (pt) 2008-07-09 2009-07-09 Estabilizante para composições de vacina, composição de vacina aquosa em massa estabilizada, método de estabilização de um ou mais flavivírus atenuados vivos, composição de vacina seca, métodos para a preparação de vacinas e kit de vacina flaviviral

Country Status (17)

Country Link
US (2) US8142795B2 (pt)
EP (3) EP2143440A1 (pt)
JP (1) JP5586598B2 (pt)
KR (1) KR101679723B1 (pt)
CN (1) CN102089002B (pt)
AR (1) AR072796A1 (pt)
AU (1) AU2009267401B2 (pt)
BR (1) BRPI0915813B1 (pt)
CA (1) CA2729758C (pt)
DK (1) DK2310048T3 (pt)
ES (1) ES2429130T3 (pt)
IL (1) IL210289A0 (pt)
MX (1) MX2011000312A (pt)
MY (1) MY150613A (pt)
TW (1) TWI460190B (pt)
WO (1) WO2010003670A1 (pt)
ZA (1) ZA201100107B (pt)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8557253B2 (en) * 2009-10-07 2013-10-15 Sanofi Pasteur Sa Stabilizing excipient for inactivated whole virus vaccine
US9056070B2 (en) * 2010-04-27 2015-06-16 Universidad Manuela Beltran Autologous biological cancer vaccine
FR2960781B1 (fr) * 2010-06-07 2013-11-22 Sanofi Pasteur Preparation d'un vaccin oral sec stabilise, compose d'un virus vivant attenue
WO2012028315A1 (en) 2010-09-02 2012-03-08 Sanofi Pasteur Sa A stabilizer for the preparation of a dry polio injectable vaccine composition
MX350096B (es) 2011-08-12 2017-08-25 Merial Inc Preservación asistida con vacío de productos biológicos, en particular de vacunas.
EP3246400B1 (en) 2012-01-09 2019-10-23 Sanofi Pasteur Biologics, LLC Purification of herpes virus
CA2873655C (en) * 2012-05-14 2021-04-06 Teijin Limited Radiation sterilization-resistant protein composition
EP2852662B1 (en) 2012-05-21 2020-09-16 Sanofi Pasteur Limited Herpesvirus compositions and related methods
SG10201912291YA (en) 2012-07-24 2020-02-27 Sanofi Pasteur Vaccine compositions
AU2013295016A1 (en) 2012-07-24 2015-01-29 Sanofi Pasteur Vaccine compositions for prevention against dengue virus infection
US9314519B2 (en) * 2012-08-21 2016-04-19 Intervet Inc. Liquid stable virus vaccines
BR112015012515B1 (pt) 2012-11-30 2023-04-11 Sanofi Pasteur Uso de antígenos, construções de ácido nucleico ou vetores virais capazes de expressar uma partícula do tipo vírus (vlp) da dengue e de uma vacina contra sarampo, uma vacina contra caxumba e uma vacina contra rubéola
US9480739B2 (en) 2013-03-15 2016-11-01 Intervet Inc. Bovine virus vaccines that are liquid stable
US9393298B2 (en) 2013-03-15 2016-07-19 Intervet Inc. Liquid stable bovine virus vaccines
AR097762A1 (es) 2013-09-27 2016-04-13 Intervet Int Bv Formulaciones secas de vacunas que son estables a temperatura ambiente
EP3057612B1 (en) 2013-10-16 2020-05-06 Merck Sharp & Dohme Corp. Method of obtaining thermostable dried vaccine formulations
EP3057978B1 (en) 2013-10-16 2022-09-14 Merck Sharp & Dohme LLC Method of microwave vacuum drying spherical-shaped pellets of biological materials
AR099470A1 (es) 2014-02-17 2016-07-27 Intervet Int Bv Vacunas de virus de aves de corral líquidas
TWI670085B (zh) 2014-02-19 2019-09-01 荷蘭商英特威國際公司 液體穩定之豬病毒疫苗
NZ726315A (en) 2014-05-14 2018-04-27 Merial Inc Methods for freeze-drying and rehydrating biologics
TWI852899B (zh) 2014-09-02 2024-08-21 法商賽諾菲巴斯德公司 疫苗組合物
DK3197487T3 (da) 2014-09-26 2022-09-05 Seqirus Uk Ltd Vaccination af immunsvækkede individer
EP3316905A1 (en) 2015-07-03 2018-05-09 Sanofi Pasteur Concomitant dengue and yellow fever vaccination
US10004795B2 (en) 2015-09-08 2018-06-26 Fundacao Butantan Process for preparing an attenuated tetravalent dengue vaccine
CN106667944A (zh) * 2015-11-11 2017-05-17 北京泰德制药股份有限公司 含有前列腺素类药物的缓释制剂
TW202309276A (zh) * 2016-08-03 2023-03-01 美商武田疫苗股份有限公司 用於與經改良之調配物一起穩定黃病毒的組成物及方法
US11166915B2 (en) * 2016-09-16 2021-11-09 Leukocare Ag Method for obtaining efficient viral vector-based compositions for vaccination or gene therapy
GB201704126D0 (en) * 2017-03-15 2017-04-26 Blom Nihlén Kim Andrea Vaccine
CA3062549A1 (en) * 2017-05-15 2018-11-22 Janssen Vaccines & Prevention B.V. Stable virus-containing composition
EP3681998A1 (en) 2017-09-11 2020-07-22 IMBA-Institut für Molekulare Biotechnologie GmbH Tumor organoid model
WO2019069130A1 (en) 2017-10-05 2019-04-11 Sanofi Pasteur COMPOSITIONS FOR RECALL VACCINATION AGAINST DENGUE
MY209364A (en) * 2017-10-16 2025-07-03 Serum Institute Of India Pvt Ltd Stable vaccine compositions comprising inter alia live attenuated recombinant flavivirus and process for preparation thereof
WO2019112921A1 (en) 2017-12-07 2019-06-13 Merck Sharp & Dohme Corp. Formulations of dengue virus vaccine compositions
AR113996A1 (es) * 2017-12-22 2020-07-08 Intervet Int Bv Vacunas líquidas de virus envueltos vivos
CN108938574B (zh) * 2018-08-14 2020-10-16 江苏省农业科学院 猪伪狂犬病活疫苗冻干耐热保护剂、其制备方法及用途
US20220193222A1 (en) * 2018-11-30 2022-06-23 Vaccine Stabilization Institute Viral formulations containing amino acids
KR102544928B1 (ko) * 2022-12-28 2023-06-20 주식회사 중앙백신연구소 아미노산을 유효성분으로 함유하는 동물용 백신 또는 진단용 항원의 안정성 증진용 조성물 및 이의 용도
WO2026052882A1 (en) * 2024-09-09 2026-03-12 Valneva Austria Gmbh Yellow fever virus (yfv) compositions and production thereof

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3162019A (en) 1962-11-16 1964-12-22 Bethlehem Steel Corp Method and apparatus for freezing liquids to be used in a freeze-drying process
GB1195363A (en) 1966-06-17 1970-06-17 Struthers Scientific Int Corp Freeze Drying
US3313032A (en) 1966-07-28 1967-04-11 George J Malecki Freeze-drying process and apparatus
US3655838A (en) 1969-03-20 1972-04-11 Organon Method of pelletizing analytical or immunological reagents
DE2659546A1 (de) 1976-12-30 1978-07-13 Boehringer Mannheim Gmbh Verfahren zur herstellung von gefrorenen granulaten
US4211015A (en) 1978-01-18 1980-07-08 Baxter Travenol Laboratories, Inc. Method and apparatus for making novel particulate compositions
FR2505657A1 (fr) * 1981-05-13 1982-11-19 Pasteur Institut Perfectionnements apportes aux agents de stabilisation de virus vivants pour la preparation de vaccins, et vaccins stabilises contenant lesdits agents de stabilisation
GB8802142D0 (en) * 1988-02-01 1988-03-02 Air Prod & Chem Method of freezing liquid & pasty products & freezer for carrying out said method
EP1018556B1 (en) 1991-09-19 2005-11-23 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the Secretary of the Department of HEALTH AND HUMAN SERVICES Chimeric and/or growth-restricted flaviviruses
US5307640A (en) 1993-01-25 1994-05-03 E. I. Du Pont De Nemours And Company Apparatus and method for producing frozen particles of a liquid
US5922253A (en) 1995-05-18 1999-07-13 Alkermes Controlled Therapeutics, Inc. Production scale method of forming microparticles
WO1996040933A1 (en) 1995-06-07 1996-12-19 The Government Of The United States Of America, Represented By The Secretary Department Of Health And Human Services Infectious dengue 2 virus pdk-53 as quadravalent vaccine
FR2742756B1 (fr) * 1995-12-22 1998-04-03 Pasteur Merieux Serums Vacc Stabilisants pour vaccins vivants, vaccins les contenant et procedes pour leur preparation
IL120202A (en) 1996-03-07 2001-03-19 Akzo Nobel Nv Container with freeze-dried vaccine components
US6962708B1 (en) * 1997-02-28 2005-11-08 Acambis, Inc. Chimeric flavivirus vaccines
EP0977587B1 (en) 1997-02-28 2005-06-15 Acambis Inc. Chimeric flavivirus vaccines
BRPI9701774B8 (pt) 1997-04-11 2015-09-29 Fundação Oswaldo Cruz Fiocruz cdna mutante e infeccioso do vírus da febre amarela, constructo de dna, vírus recombinante de febre amarela e vacina para humanos contra infecções de febre amarela.
US6210683B1 (en) * 1997-09-05 2001-04-03 Merck & Co., Inc. Stabilizers containing recombinant human serum albumin for live virus vaccines
JP2002540169A (ja) 1999-03-26 2002-11-26 ウォルター リード アーミー インスティテュート オブ リサーチ 弱毒化デング熱１型ウイルスワクチン
US6537557B1 (en) 1999-03-26 2003-03-25 The United States Of America As Represented By The Secretary Of The Army Attenuated dengue-4 virus vaccine
WO2000057909A2 (en) 1999-03-26 2000-10-05 Walter Reed Army Institute Of Research Attenuated dengue-2 virus vaccine
CA2368790A1 (en) 1999-03-26 2000-10-05 Walter Reed Army Institute Of Research Attenuated dengue-3 virus vaccine
ATE526411T1 (de) 2000-02-16 2011-10-15 Us Gov Health & Human Serv Avirulente, immunogene flavivirus-chimäre
ATE412738T1 (de) 2000-05-30 2008-11-15 Univ Mahidol Attenuierte stammen von denguevirus und ihre verwendungen in impfstoffzusammensetzungen
US6862890B2 (en) 2001-01-30 2005-03-08 Board Of Regents, University Of Texas System Process for production of nanoparticles and microparticles by spray freezing into liquid
AT410634B (de) * 2001-02-21 2003-06-25 Franz X Dr Heinz Attenuierte lebendimpfstoffe
GB2372991B (en) 2001-03-09 2004-11-17 Fiocruz Fundacao Oswaldo Cruz Flavivirus expression vector
CA2966716C (en) 2001-05-22 2019-11-26 The Government Of The United States Of America, As Represented By The Cretary, Department Of Health And Human Services Development of mutations useful for attenuating dengue viruses and chimeric dengue viruses
DE10124902A1 (de) 2001-05-22 2002-11-28 Bayer Ag Partikuläre Feststoffe oberflächenaktiver Verbindungen
CN1551782A (zh) 2001-06-01 2004-12-01 ��������ķ������ 嵌合黄病毒载体
US20050002968A1 (en) 2002-01-15 2005-01-06 Monath Thomas P. Flavivirus vaccines
KR101074175B1 (ko) 2002-01-15 2011-10-14 사노피 파스테르 바이오로직스 씨오 플라비바이러스 백신
US7476390B2 (en) 2002-02-26 2009-01-13 Maxygen, Inc. Flavivirus antigens
WO2003087327A2 (en) * 2002-04-11 2003-10-23 Medimmune Vaccines, Inc. Preservation of bioactive materials by freeze dried foam
US20030215455A1 (en) * 2002-05-14 2003-11-20 Bailey Reynolds Vaccine stabilizer and method of use
US20040259224A1 (en) 2002-05-31 2004-12-23 Farshad Guirakhoo Tetravalent Dengue vaccines
WO2004045529A2 (en) 2002-11-15 2004-06-03 Acambis, Inc. West nile virus vaccine
WO2004052293A2 (en) * 2002-12-11 2004-06-24 Hawaii Biotech, Inc. Recombinant vaccine against flavivirus infection
AU2005263465B2 (en) 2004-07-23 2010-07-29 Bayer Healthcare Llc Sterile freezing, drying, storing, assaying and filling process (SFD-SAF process) (pellet freeze-drying process for parenteral biopharmaceuticals)
CN101238144B (zh) 2005-06-17 2012-09-05 赛诺菲巴斯德有限公司 登革血清型1减毒株
CA2611954C (en) 2005-06-17 2014-01-28 Sanofi Pasteur Dengue serotype 2 attenuated strain
US20070031450A1 (en) * 2005-08-04 2007-02-08 Wyeth Stabilizers for veterinary vaccines
KR101357685B1 (ko) * 2005-11-21 2014-02-06 사노피 파스퇴르 리미티드 / 사노피 파스퇴르 리미떼 재조합 바이러스용 안정화 제형
FR2903605A1 (fr) * 2006-07-12 2008-01-18 Sanofi Pasteur Sa Methode d'immunisation contre les quatres serotypes de la dengue
US20100129379A1 (en) 2006-09-25 2010-05-27 John Carpenter Stabilized antibody formulations and uses thereof
FR2906724B1 (fr) * 2006-10-04 2009-03-20 Sanofi Pasteur Sa Methode d'immunisation contre les 4 serotypes de la dengue.
MX2009004862A (es) 2006-11-07 2009-07-17 Sanofi Pasteur Biologics Co Estabilizacion de vacunas por liofilizacion.
FR2909286B1 (fr) * 2006-12-01 2012-06-08 Sanofi Pasteur Methode d'immunisation contre les 4 serotypes de la dengue
WO2009014774A1 (en) * 2007-04-06 2009-01-29 Inviragen, Inc. Methods and compositions for live attenuated viruses

Also Published As

Publication number Publication date
MX2011000312A (es) 2011-03-01
DK2310048T3 (da) 2013-10-07
CA2729758C (en) 2017-03-07
MY150613A (en) 2014-01-30
US20100015180A1 (en) 2010-01-21
EP2310048A1 (en) 2011-04-20
ES2429130T3 (es) 2013-11-13
IL210289A0 (en) 2011-03-31
BRPI0915813B1 (pt) 2022-02-08
CA2729758A1 (en) 2010-01-14
JP2011527300A (ja) 2011-10-27
TW201014868A (en) 2010-04-16
CN102089002B (zh) 2014-12-10
US8142795B2 (en) 2012-03-27
CN102089002A (zh) 2011-06-08
EP2143440A1 (fr) 2010-01-13
EP2687229A1 (en) 2014-01-22
AU2009267401B2 (en) 2014-12-11
JP5586598B2 (ja) 2014-09-10
KR101679723B1 (ko) 2016-11-25
EP2310048B1 (en) 2013-09-11
AU2009267401A1 (en) 2010-01-14
TWI460190B (zh) 2014-11-11
AR072796A1 (es) 2010-09-22
US20130028934A1 (en) 2013-01-31
ZA201100107B (en) 2012-03-28
WO2010003670A1 (en) 2010-01-14
KR20110053325A (ko) 2011-05-20

Similar Documents

Publication Publication Date Title
BRPI0915813A2 (pt) estabilizante e composição de vacina compreendendo um ou mais flavivírus atenuados vivos
ATE523207T1 (de) Stabilisatoren für gefriergetrocknete impfstoffe
MX2009004862A (es) Estabilizacion de vacunas por liofilizacion.
BR112015011244A8 (pt) análogos de compstatina de reação celular, ação longa ou direcionados e composições e métodos relacionados
BRPI0909630B8 (pt) composição em suspensão aquosa particularmente adequada para injeção dentro do olho
UA112281C2 (uk) Стабільні інсектицидні композиції і способи їх отримання
AR065467A1 (es) Composiciones de tabaco y metodos de preparacion
BR112018013104A2 (pt) composição e método para crescimento de cabelos ou pelos
BR112014015908A8 (pt) composição
BR112016003127A2 (pt) “composições e métodos para modular rna”
BR112014004444A2 (pt) composições e métodos que compreendem uma variante de enzima lipolítica
EA201001639A1 (ru) Композиции и способы их получения и применения
BR112014009376A2 (pt) composições
EP2528578A4 (en) DENTAL COMPOSITION USING A CALCIUM SOURCE
BR112013003145A2 (pt) composição para controle de artrópodes nocivos e método para o controle de artrópodes nocivos
BRPI0918058A8 (pt) Uso de composições de composto fungicida para o controle de certos fungos da ferrugem
BRPI0823272A2 (pt) conceito com recheio e método
BR112015001728B8 (pt) composições de condicionador
BR112017023720A2 (pt) formulações de inibidor de corrosão
BR112017022821A2 (pt) solução aquosa homogênea de quitosana injetável apresentando um ph próximo do ph fisiológico
EP2898923A3 (en) Isoflavones for regulating sirtuin gene expression
BR112016022749A2 (pt) compostos de azole substituído por amido como inibidores de tnks1 e/ou tnks2
BRPI0709361B8 (pt) composição, métodos para a preparação de um alimento e método para o tratamento de listeria
BR112012019920A2 (pt) derivados de piridazina úteis como agonístas de canabinoide-2.
BR112013005532A2 (pt) agente terapêutico para dor

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 09/07/2009, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.